Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of immunotherapy

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CJI.0b013e3181dcd260PMID 20551840
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

  2010cited by this paper
• Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM).

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4

  2009cited by this paper
• Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

  2009cited by this paper
• Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade

  2009influential reference
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

  2009cited by this paper
• Phase I/II trial of tremelimumab in patients with metastatic melanoma.

  2009cited by this paper
• Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma

  2009cited by this paper
• Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study

  2008cited by this paper
• CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

  2008cited by this paper
• Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.

  2008influential reference
• Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

  2008influential reference
• Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

  2008cited by this paper
• Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer

  2008cited by this paper
• EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results

  2008cited by this paper
• Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC)

  2008cited by this paper
• CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?

  2008cited by this paper
• Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

  2008cited by this paper
• Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine

  2008cited by this paper
• First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view

  2008cited by this paper
• Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody

  2008cited by this paper
• Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)

  2008cited by this paper
• Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

  2008influential reference
• Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody

  2008cited by this paper
• CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.

  2008cited by this paper
• Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment

  2008cited by this paper
• Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

  2008cited by this paper
• Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies

  2008cited by this paper
• Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

  2008cited by this paper
• Next generation of immunotherapy for melanoma.

  2008cited by this paper
• Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

  2008cited by this paper
• CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

  2008cited by this paper
• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

  2007cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2007cited by this paper
• Update on anti-CTLA-4 antibodies in clinical trials

  2007cited by this paper
• A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

  2007cited by this paper
• Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.

  2007cited by this paper
• Prospect of Targeting the CD40 Pathway for Cancer Therapy

  2007cited by this paper
• Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

  2007cited by this paper
• Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.

  2007cited by this paper
• An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites

  2007cited by this paper
• Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy

  2007cited by this paper
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

  2006cited by this paper
• A review of rituximab in cutaneous medicine.

  2006cited by this paper
• Response to Comment on “Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade”

  2006cited by this paper
• Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma

  2006cited by this paper
• Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma

  2006cited by this paper
• Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

  2005cited by this paper
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

  2005cited by this paper
• Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells

  2005cited by this paper
• Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting.

  2005cited by this paper
• Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

  2005cited by this paper
• Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

  2005cited by this paper
• DURABLE RESPONSES AND LONG-TERM PROGRESSION- FREE SURVIVAL OBSERVED IN A PHASE II STUDY OF MDX- 010 ALONE OR IN COMBINATION WITH DACARBAZINE (DTIC) IN METASTATIC MELANOMA.

  2005cited by this paper
• Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade

  2005cited by this paper
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

  2004cited by this paper
• Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy

  2004cited by this paper
• Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

  2004cited by this paper
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  2003cited by this paper
• Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

  2003cited by this paper
• Modulation of tryptophan catabolism by regulatory T cells

  2003cited by this paper
• Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.

  2002cited by this paper
• Coley's toxin: historical perspective.

  2002cited by this paper
• CTLA-4–Ig regulates tryptophan catabolism in vivo

  2002cited by this paper
• CTLA-4: new insights into its biological function and use in tumor immunotherapy

  2002cited by this paper
• Immunotherapy for melanoma.

  2002cited by this paper
• CTLA-4 regulates induction of anergy in vivo.

  2001cited by this paper
• CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

  2001cited by this paper
• Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

  2001cited by this paper
• Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine

  2001cited by this paper
• T-cell regulation by CD28 and CTLA-4

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

  1999cited by this paper
• CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.

  1999cited by this paper
• Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

  1999cited by this paper
• Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

  1999cited by this paper
• In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.

  1999cited by this paper
• Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Can Regulate Dendritic Cell–induced Activation and Cytotoxicity of CD8+ T Cells Independently of CD4+T Cell Help

  1999cited by this paper
• Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.

  1999cited by this paper
• Thymocyte development is normal in CTLA-4-deficient mice.

  1997cited by this paper
• Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.

  1997cited by this paper
• Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo.

  1996cited by this paper
• Enhancement of Antitumor Immunity by CTLA-4 Blockade

  1996cited by this paper
• CD28/B7 system of T cell costimulation.

  1996cited by this paper
• Prognostic factors in 1,521 melanoma patients with distant metastases.

  1995cited by this paper
• Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

  1995cited by this paper
• Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

  1995cited by this paper
• Recombinant Interleukin‐2

  1994cited by this paper
• Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

  1992cited by this paper
• CTLA-4 is a second receptor for the B cell activation antigen B7

  1991cited by this paper
• Clinical Use of Biologic Response Modifiers in Cancer Treatment: An Overview Part II. Colony-Stimulating Factors and Interleukin-2

  1991cited by this paper
• A new member of the immunoglobulin superfamily—CTLA-4

  1987cited by this paper
• Melanoma: therapeutic options with recombinant interferons.

  1985cited by this paper
• Analysis of survival by tumor response.

  1983cited by this paper

• Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors

  2023cites this paper
• Monoclonal Antibodies: What the Diagnostic Neuroradiologist Needs to Know

  2023cites this paper
• Dendritic cell-based cancer immunotherapy for pancreatic cancer.

  2018cites this paper
• Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

  2016cites this paper
• Cancer immunology - development of novel anti-cancer therapies.

  2015cites this paper
• Cancer vaccines

  2015cites this paper
• Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study.

  2015cites this paper
• Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti‐tumor effect of the CTLA‐4 blockade in an HLA‐DR transgenic mouse model of prostate cancer

  2014cites this paper
• Novel insights/translational implication from the emerging biology of melanoma.

  2014cites this paper
• Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy

  2014cites this paper
• Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab

  2013cites this paper
• Endocrine side effects induced by immune checkpoint inhibitors.

  2013cites this paper
• Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts

  2013cites this paper
• Intracellular CTLA4 and Regulatory T Cells in Patients with Laryngeal Squamous Cell Carcinoma

  2013cites this paper
• Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab

  2013cites this paper
• Analysis of Innate and Adaptive Immune Responses to Listeria Monocytogenes Infection

  2013cites this paper
• Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

  2013cites this paper
• Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses.

  2013cites this paper
• Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease.

  2012cites this paper
• 3rd Pavia international symposium on advanced kidney cancer

  2012cites this paper
• Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

  2012cites this paper
• Central and effector memory CD4 and CD8 T-cell responses to tumor-associated antigens.

  2012cites this paper
• Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models.

  2012cites this paper
• Sequential Immunotherapy by Vaccination With GM-CSF–expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors

  2012cites this paper
• Disrupting the Networks of Cancer

  2012cites this paper
• Which therapy for which patient

  2012cites this paper
• Butler T Cells + CD 8 Educated − Establishment of Antitumor Memory in Humans Using in Vitro

  2011cites this paper
• Immuno-Therapy with Anti-CTLA4 Antibodies in Tolerized and Non-Tolerized Mouse Tumor Models

  2011cites this paper
• Introduction: Cancer vaccines—mechanisms and a clinical overview

  2011cites this paper
• CTLA4 gene variants in autoimmunity and cancer: a comparative review.

  2011cites this paper
• Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy.

  2011cites this paper
• Potential targets for pancreatic cancer immunotherapeutics.

  2011cites this paper
• Establishment of Antitumor Memory in Humans Using in Vitro–Educated CD8+ T Cells

  2011cites this paper
• Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines

  2011cites this paper
• Clinical development of the anti-CTLA-4 antibody tremelimumab.

  2010cites this paper
• Engineering human single-chain T cell receptors

  2010cites this paper
• Translating insights from persistent LCMV infection into anti-HIV immunity

  2010cites this paper
• Neuroradiologist Needs to Know Monoclonal Antibodies: What the Diagnostic

  year unknowncites this paper